Skip to main content

Primary Visceral Leishmaniasis

4
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
2 programs
2
LXE408Phase 21 trial
LXE408Phase 21 trial
Active Trials
NCT05957978Completed52Est. Nov 2025
NCT05593666Completed101Est. Dec 2025
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Liposomal amphotericin BPhase 2
Paladin Labs
Paladin LabsQC - Saint-Laurent
1 program
1
Liposomal amphotericin BPhase 21 trial
Active Trials
NCT01067443Completed151Est. Jun 2011
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
Liposomal amphotericin BPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozLXE408
SandozLXE408
Paladin LabsLiposomal amphotericin B

Clinical Trials (3)

Total enrollment: 304 patients across 3 trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Start: Mar 2024Est. completion: Nov 202552 patients
Phase 2Completed

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Start: Dec 2022Est. completion: Dec 2025101 patients
Phase 2Completed
NCT01067443Paladin LabsLiposomal amphotericin B

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

Start: Mar 2010Est. completion: Jun 2011151 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.